JP7830131B2 - リポソーム化アナマイシンを再構成する方法 - Google Patents

リポソーム化アナマイシンを再構成する方法

Info

Publication number
JP7830131B2
JP7830131B2 JP2021577862A JP2021577862A JP7830131B2 JP 7830131 B2 JP7830131 B2 JP 7830131B2 JP 2021577862 A JP2021577862 A JP 2021577862A JP 2021577862 A JP2021577862 A JP 2021577862A JP 7830131 B2 JP7830131 B2 JP 7830131B2
Authority
JP
Japan
Prior art keywords
anamycin
liposomal
bag
vials
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523872A5 (https=
JP2023523872A (ja
Inventor
ピッカー ドナルド
プリーベ ヴァルデマル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Moleculin Biotech Inc
Original Assignee
University of Texas System
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Moleculin Biotech Inc filed Critical University of Texas System
Publication of JP2023523872A publication Critical patent/JP2023523872A/ja
Publication of JP2023523872A5 publication Critical patent/JP2023523872A5/ja
Application granted granted Critical
Publication of JP7830131B2 publication Critical patent/JP7830131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2021577862A 2019-06-28 2020-06-25 リポソーム化アナマイシンを再構成する方法 Active JP7830131B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868190P 2019-06-28 2019-06-28
US62/868,190 2019-06-28
PCT/US2020/039621 WO2020264161A1 (en) 2019-06-28 2020-06-25 Method of reconstituting liposomal annamycin

Publications (3)

Publication Number Publication Date
JP2023523872A JP2023523872A (ja) 2023-06-08
JP2023523872A5 JP2023523872A5 (https=) 2023-07-14
JP7830131B2 true JP7830131B2 (ja) 2026-03-16

Family

ID=74061076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577862A Active JP7830131B2 (ja) 2019-06-28 2020-06-25 リポソーム化アナマイシンを再構成する方法

Country Status (15)

Country Link
US (2) US12257262B2 (https=)
EP (1) EP3990041B1 (https=)
JP (1) JP7830131B2 (https=)
KR (1) KR20220027941A (https=)
CN (2) CN114728101B (https=)
AU (2) AU2020302784A1 (https=)
BR (1) BR112021026480A2 (https=)
CA (1) CA3144443A1 (https=)
ES (1) ES3049663T3 (https=)
IL (1) IL289433B1 (https=)
MX (1) MX2021015667A (https=)
PL (1) PL3990041T3 (https=)
SG (1) SG11202113005SA (https=)
TW (2) TWI857086B (https=)
WO (1) WO2020264161A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
EP4061810A4 (en) * 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032145A1 (en) 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
WO2018048752A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4863739A (en) 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
TWI433693B (zh) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
ES2637072T3 (es) * 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN107569508A (zh) * 2016-07-05 2018-01-12 江苏竞诺择生物医药科技有限公司 一种治疗造血系统增殖性疾病的药用组合物
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN112955145A (zh) 2018-09-04 2021-06-11 密涅瓦神经科学有限公司 使用苯氧丙胺化合物治疗疼痛的方法
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
EP4061810A4 (en) 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032145A1 (en) 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
WO2018048752A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Chemother Pharmacol，1996年，Vol.39，pp.103-108
薬剤学，2014年，Vol.74(1)，pp.57-62

Also Published As

Publication number Publication date
KR20220027941A (ko) 2022-03-08
AU2024203593A1 (en) 2024-07-11
ES3049663T3 (en) 2025-12-17
AU2024203593B2 (en) 2025-08-14
EP3990041B1 (en) 2025-08-06
IL289433B1 (en) 2026-01-01
US11980634B2 (en) 2024-05-14
US20220105116A1 (en) 2022-04-07
CN114728101A (zh) 2022-07-08
TWI857086B (zh) 2024-10-01
CN114728101B (zh) 2023-07-14
SG11202113005SA (en) 2021-12-30
EP3990041A4 (en) 2023-07-12
WO2020264161A1 (en) 2020-12-30
TW202114704A (zh) 2021-04-16
TW202500161A (zh) 2025-01-01
MX2021015667A (es) 2022-04-18
US20240024345A1 (en) 2024-01-25
CA3144443A1 (en) 2020-12-30
PL3990041T3 (pl) 2026-02-23
CN116785242A (zh) 2023-09-22
JP2023523872A (ja) 2023-06-08
US12257262B2 (en) 2025-03-25
IL289433A (en) 2022-02-01
EP3990041A1 (en) 2022-05-04
BR112021026480A2 (pt) 2022-02-08
AU2020302784A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US11980634B2 (en) Method of reconstituting liposomal annamycin
CN116763733A (zh) 脂质体组合物及医药组合物
RS63400B1 (sr) Lipozomska formulacija za upotrebu u lečenju kancera
JP2025506895A (ja) 低吸着性グリブリドキット、製剤および方法
CN114641296B (zh) 制备安那霉素脂质体前体冻干物
JP2023523872A5 (https=)
HK40073244A (en) Method of reconstituting liposomal annamycin
HK40073244B (en) Method of reconstituting liposomal annamycin
CN120835787A (zh) 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法
CN105560182A (zh) 注射用卡巴他赛组合物及其制备方法
CN114712309B (zh) 一种人参皂苷多西他赛脂质体、其制备方法和应用
CN103877013A (zh) 一种细辛脑注射剂及其制备方法
WO2005072776A2 (en) Liposomal formulations of the antineoplastic agents
PL190077B1 (pl) Liposomowy preparat doksorubicyny, sposób jego wytwarzania oraz przeciwnowotworowa kompozycja farmaceutyczna zawierająca ten preparat
HK40009643A (en) Liposomal formulation for use in the treatment of cancer
HK40009643B (en) Liposomal formulation for use in the treatment of cancer

Legal Events

Date Code Title Description
A59 Written plea

Free format text: JAPANESE INTERMEDIATE CODE: A59

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260304

R150 Certificate of patent or registration of utility model

Ref document number: 7830131

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150